Novo Nordisk Slips, Fresenius & Telefónica Earnings

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
-  Novo Nordisk’s next-generation weight-loss drug CagriSema isn’t even on the market yet, but the company’s chief executive officer is already batting back suggestions that the drug is obsolete following the release of disappointing trial results on Monday. 
- Fresenius Medical Care  fell after it posted a disappointing outlook where it expects broadly flat revenue and said profit could potentially decline this fiscal year.
- Telefónica posted fourth-quarter earnings that met analyst estimates as growth in Spain and Brazil offset weakness in other European markets.

See omnystudio.com/listener for privacy information.